Women continue to represent a tiny sliver of investors in Silicon Valley and other tech hubs. But in health tech, the divide isn’t quite as stark as in other sectors.
New research from the early-stage investment fund Rock Health found that women make up about 11 percent of health-tech partners, a slight decrease from 11.4 percent in 2015. The average overall for venture capital is just 7 percent.
Click below to view the latest news and updates from Arboretum Ventures.
Pear Therapeutics, the leader in prescription digital therapeutics, today announced that it has received an Expedited Access Pathway (EAP) designation from the U.S. Food and Drug Administration (FDA) for its reSET-O™ Prescription Digital Therapeutic, the first of its kind designed for treating Opioid Use Disorder (OUD).
Strata Oncology, Inc. (Strata), a precision oncology company, announced a collaboration with the University of California San Francisco (UCSF) to launch Stratify Prostate™ a unique initiative focused on expanding access to tumor sequencing nationwide for men with advanced prostate cancer and to dramatically accelerate enrollment into relevant targeted therapy trials.
Pear Therapeutics, the leader in a new era of prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Pear’s De Novo request, allowing the company to market reSET® for the treatment of patients with substance use disorder (SUD) under a new class of treatment. This is the first time that the FDA has cleared a Prescription Digital Therapeutic with claims to improve clinical outcomes in a disease.
Delphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology, announced today that the SoftVue Discover Breast Ultrasound Prospective Case Collection project has launched, enrolling the first patient.
NxThera, Inc., a medical device company pioneering the application of its convective radiofrequency thermal therapy to treat endourological conditions, today announced that new data from the first post-market clinical evaluation of its minimally invasive Rezūm System demonstrated significant, safe and effective urinary symptom relief, improved quality of life and preserved sexual function for men treated for benign prostatic hyperplasia (BPH).
The American Society for Clinical Pathology (ASCP) announces the selection of ArborMetrix as its technology and analytics partner to power the National Pathology Quality Registry (NPQR).
Swift Biosciences, a leading provider of innovative library prep solutions for next-generation sequencing (NGS), today announced the launch of a new single-cell methylation sequencing method based on its Accel-NGS® Adaptase™ technology, an efficient and robust NGS-prep solution for whole-genome bisulfite sequencing at single-cell resolution.
Swift Biosciences, a leading provider of innovative library prep solutions for genomic sequencing, today announced the completion of a Series D funding raise of $12.2 million. The company also announced the addition of two new directors to its board, positioning the company for accelerated growth.
No more posts to load.
Load More Posts